EGFR L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) improve the clinical outcomes of EGFR-mutant non-small cell lung cancer (NSCLC) patients significantly, however, acquired resistance occurs almost inevitably. The underlying mechanisms of osimertinib resistance and treatment str...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Transl Med
Hlavní autoři: Ma, Lei, Chen, Rui, Wang, Fang, Ma, Li-Li, Yuan, Ming-Ming, Chen, Rong-Rong, Liu, Jiang
Médium: Artigo
Jazyk:Inglês
Vydáno: AME Publishing Company 2019
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6545316/
https://ncbi.nlm.nih.gov/pubmed/31205925
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2019.04.37
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky